Clamovet

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clamovet

Property Description
Active ingredients Amoxicillin and Clavulanic acid
Form Oral tablets, Powder for oral suspension, Granules
Pharmacological class Antibiotic/Beta-Lactamase Inhibitor Combination
General use Treating infections caused by susceptible bacteria
Origin Semisynthetic

Clamovet is fundamentally a systemic combination drug used to treat bacterial infections, classified within the specialized Antibiotic/Beta-Lactamase Inhibitor Combination pharmacological class. Amoxicillin, the primary agent, is a semisynthetic penicillin derivative that inhibits bacterial cell wall construction. The medication is an oral preparation typically available in various forms, including tablets and as a powder for suspension. This drug is applied in managing common infections of the skin and respiratory tract.


The Dual Composition: Amoxicillin and Clavulanic Acid

The composition includes the two active ingredients: the antibiotic Amoxicillin and Clavulanic acid (sourced as potassium clavulanate), forming a fixed-dosage product. Clavulanic acid is not a primary antibiotic but rather a beta-lactamase inhibitor, acting as a suicide inhibitor by binding to and irreversibly neutralizing bacterial defense enzymes. The therapeutic synergy of this combination is established through formulations containing Amoxicillin and Clavulanic acid, known internationally as Co-Amoxiclav, defining its distinguishing feature compared to single-ingredient antibiotics.


Clamovet's General Benefit: Overcoming Bacterial Resistance

The strategic pairing of these two components provides Clamovet's defining utility: the effective reduction of bacterial resistance. By protecting the Amoxicillin from enzymatic degradation, the Clavulanic acid component ensures the antibiotic remains functional, thereby extending its antibacterial spectrum. The inclusion of the beta-lactamase inhibitor widens the antibacterial spectrum of Amoxicillin to include many beta-lactamase-producing strains. This combination approach allows the drug to manage a range of infections, providing a means of achieving a therapeutic response even in cases involving treatment-resistant strains.

Regulatory References

  1. Co-Amoxiclav

What side effects are possible with Clamovet?

Possible Side Effects and Safety Information

Official government regulatory bodies have documented that Clamovet, a fluoroquinolone antibiotic, is associated with a risk of serious, disabling, and potentially irreversible adverse reactions. These serious events may involve multiple body systems and have resulted in the FDA applying its strongest warning (Boxed Warning) to this class of medicine.


Key Adverse Reaction Categories

  • Musculoskeletal and Nervous System: This medicine is officially linked to serious adverse reactions affecting the tendons, muscles, joints, peripheral nerves (peripheral neuropathy), and the central nervous system. These reactions may occur together in the same patient.
  • Serious/Clinically Significant Adverse Reactions: Documented serious risks include tendinitis and tendon rupture (most commonly the Achilles tendon), worsening of muscle weakness in patients with myasthenia gravis, severe hypersensitivity reactions (e.g., anaphylaxis, angioedema), and disturbances of heart rhythm (QT prolongation).
  • Psychiatric and CNS Effects: Serious effects may also involve the central nervous system, including confusion, depression, hallucinations, anxiety, and suicidal thoughts or actions.

Risk Factors and Safety Notes

Regulatory information identifies that the risk of certain serious adverse reactions, particularly tendon injury, is higher in specific patient groups. These groups include patients over 60 years of age, those with kidney disease, solid-organ transplant recipients, and individuals concurrently receiving systemic corticosteroids.

Adverse reactions may manifest hours to weeks after starting treatment and, once developed, the associated disability can persist for months or years, even after the medicine is discontinued. The medicine is contraindicated (must not be used) in patients with a history of serious adverse reactions to any quinolone or fluoroquinolone antibiotic. Caution is also noted for patients with a known risk for QT interval prolongation or those with epilepsy/CNS disorders.

Common Adverse Reactions

Commonly reported side effects, classified by frequency in official documents, primarily involve the gastrointestinal system, such as nausea, vomiting, and diarrhea. Other common reports include headache, dizziness, and mild skin rashes.

Overdose and Emergency Response

🆘 Overdose and When to Seek Help

Overdose with Clamovet, an opioid pain medicine, is a serious medical emergency that can be fatal. It is primarily characterized by severe depression of the central nervous system and respiratory function.

Signs and Symptoms of Overdose

Symptoms that require immediate emergency attention often include, but are not limited to:

  • Respiratory Distress: Breathing that is slow, shallow, or difficult, or has stopped completely.
  • Unresponsiveness: Inability to wake up, severe sleepiness, or falling into a coma.
  • Physiological Changes: Pinpoint pupils (miosis), cold/clammy skin, and a limp body.
  • Abnormal Sounds: Choking or gurgling noises from the mouth.

When to Seek Immediate Medical Help

If you or someone you are caring for exhibits any signs of respiratory problems, severe sleepiness, or an inability to respond or wake up, call 911 or your local emergency number immediately.

Overdose Risk Factors

Serious risks of overdose, including fatal outcomes, are associated with taking higher doses of this medication. The risk is significantly increased when Clamovet is used in combination with other Central Nervous System (CNS) depressants, such as benzodiazepines or alcohol, as these substances can further compound respiratory depression. For all patients taking opioid pain medicine, healthcare providers should discuss the availability and use of an opioid overdose reversal agent, such as naloxone, and provide clear directions for its emergency administration.

Therapeutic Uses of Clamovet

What Clamovet Treats: Main Uses and Benefits


The essential function of Amoxicillin/Clavulanic Acid (Clamovet) is commonly used to help with a wide range of bacterial infections across several body systems, with a key therapeutic benefit in managing infections where antibiotic resistance is a clinical concern. The combination is applied in addressing infections of the ears, lungs, sinus, skin, and urinary tract.

This medication is relevant for easing symptomatic discomfort in situations involving infections suspected to be caused by treatment-resistant strains of bacteria. It is commonly used across domains where additional symptomatic support is needed, managing symptoms such as fever, localized swelling, and acute pain in conditions like acute bacterial rhinosinusitis and otitis media.

Clamovet is also applied in clinical settings that involve acute or unstable symptom patterns affecting the skin and soft tissues, helping to address symptom clusters that may become intense or disruptive, such as deep redness and purulent discharge. This provides supportive relief when symptoms interfere with routine activities, such as those following animal bites or in specific postoperative scenarios.


Quick Fact: Relief for Acute Symptoms
This combination is considered relevant for easing symptomatic discomfort in situations involving infections suspected to be caused by treatment-resistant strains of bacteria.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Regulatory documents establish clear eligibility for Clamovet, which is based on the components amoxicillin and clavulanate potassium.

Eligibility Scope

Classification Allowed/Required Restricted/Contraindicated
Target Species Dogs and Cats Rabbits, Guinea Pigs, Hamsters, Gerbils, and Chinchillas
Allergy History None to penicillins or cephalosporins History of allergic reaction to any penicillin or cephalosporin
Breeding Status Not explicitly prohibited Use in pregnant or breeding animals has not been determined
Physiological Status Normal or mild function Serious renal dysfunction (with anuria/oliguria)

Official Restrictions

Official labeling defines specific restrictions on use. The drug is contraindicated in any animal with a known serious hypersensitivity reaction to penicillins or cephalosporins. Furthermore, it is prohibited for use in specific small herbivore species, including rabbits, guinea pigs, and hamsters, due to the potential for fatal gastrointestinal complications. Use is also contraindicated in animals with severe kidney impairment, specifically those presenting with anuria or oliguria. Caution is also advised when treating animals with hepatic or renal dysfunction, and the drug should not be used in animals maintained for breeding purposes as safety has not been definitively established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interactions for the amoxicillin and clavulanic acid combination, strictly based on regulatory government labeling. These statements reflect constraints on co-administration due to potential alterations in therapeutic effect or patient risk.

Interaction Entity Map

Interaction Type Interacting Substance/Class Constraint or Effect Described
Pharmacodynamic Bacteriostatic Antimicrobials (e.g., Chloramphenicol, Macrolides, Sulfonamides, Tetracyclines) Risk of antagonistic antibacterial effect; concurrent use is prohibited.
Pharmacodynamic Aminoglycosides Penicillins have the potential to increase the effect of this class of antibiotics.
Hypersensitivity Risk Other Penicillins / Cephalosporins Official documentation notes the potential for allergic cross-reactivity among these beta-lactam groups.

Interaction-Related Restrictions

Official regulatory documents explicitly state that the product must not be used concurrently with bacteriostatic antimicrobial medicines due to the risk of therapeutic antagonism. The interaction profile highlights that the structural relationship to other beta-lactam antibiotics, such as cephalosporins, mandates consideration of allergic cross-reactions. These regulatory constraints define the necessary prescribing boundaries for the medicine.

Mechanism of Action

The mechanism of this combination drug is defined by the synergistic action of its two components, focusing exclusively on two distinct bacterial targets, which results in bactericidal activity and counteracts the enzymatic degradation pathway of bacteria.

Direct Destruction of the Bacterial Cell Wall

This domain covers the irreversible binding and inhibition of Penicillin-Binding Proteins (PBPs) by Amoxicillin. By blocking the final cross-linking step of peptidoglycan synthesis, Amoxicillin compromises the structural integrity of the bacterial cell wall, leading to rapid osmotic instability and subsequent cell lysis (cell death).

Inhibition of the Bacterial beta-Lactamase Pathway

The second domain involves Clavulanic acid, which acts as a mechanism-based inhibitor to prevent the hydrolytic degradation of Amoxicillin. It binds irreversibly to and inactivates bacterial beta-Lactamase enzymes, which are the main defense used to degrade the antibiotic. This protective synergy ensures Amoxicillin remains intact, preserving the structural integrity of the Amoxicillin beta-lactam ring, and extends the spectrum of susceptible pathogens by counteracting the enzymatic degradation mechanism.

Mechanistic Limitations

The drug's mechanism is fundamentally constrained by the type of resistance encountered. Clavulanic acid is ineffective against resistance not mediated by beta-lactamases, such as structural modifications to the PBPs, and does not effectively neutralize certain advanced resistance forms such as Extended Spectrum beta-Lactamases (ESBLs).

Dosage and Administration Information

Official Administration Guidelines

Clamovet (amoxicillin/clavulanate potassium) is strictly an oral medication. Adherence to the prescribed regimen, which is based on the amoxicillin component, is essential for maintaining effective drug levels. Dosing for adults (over 40 kg) is typically 500 mg or 875 mg every 12 hours, or 250 mg or 500 mg every 8 hours.


Dosing and Administration Protocols

Administration Rule Guideline Detail
Timing in Relation to Meals Take at the start of a meal to enhance the absorption of the clavulanate component and reduce gastrointestinal discomfort.
Frequency and Duration Doses are divided, usually administered twice daily (q12h) or three times daily (q8h), for a duration typically ranging from 7 to 10 days.
Physical Handling Extended-release tablets must be swallowed whole and cannot be crushed, broken, or chewed. Oral suspensions require shaking well before measuring each dose.

Population-Specific Adjustments

Dosage adjustments are required for patients with impaired kidney function. For adults with a creatinine clearance (CrCl) below 30 mL/min, the dose must be reduced, and the 875 mg tablet is generally not recommended. Specific adjustments are also mandated during hemodialysis, including administering a supplementary dose during and at the end of the procedure.

Missed Dose Instructions

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Patients must never take two doses to compensate for a missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clamovet

This summary describes the types of clinical studies that were conducted on the combination of Amoxicillin and Clavulanic Acid (Clamovet), outlining what was studied and what still remains to be fully explored. The research provides context about group patterns, but these findings describe group averages and do not determine whether an individual will respond similarly.

Evidence for Use in Acute Otitis Media and Middle Ear Infections

Research has extensively explored the use of Clamovet in pediatric cohorts, typically children between the ages of 6 months and 6 years, with conditions characterized by acute or disruptive episodes such as middle ear infections. These studies, including Randomized Controlled Trials (RCTs), focused on monitoring outcomes such as the rate of changes in clinical status and the time it took for certain acute symptoms to evolve.

Evidence for Use in Respiratory and Sinus Infections

Research related to the study of both acute bacterial rhinosinusitis and community-acquired pneumonia (CAP) examined the combination primarily in adult cohorts. Studies monitored outcomes related to physical discomfort by tracking changes in specialized symptom severity scores and documenting patterns in overall patient outcomes. Trials exploring CAP reported findings were mixed regarding the differential effect when measured against Amoxicillin alone.

Long-Term Outcomes and Follow-up in Studies

Study designs generally focus on the acute infection phase, with follow-up durations being limited. For most indications, the observation period extends up to a few weeks post-treatment, or up to 30 days for respiratory and tissue infections studied in certain cohorts. Long-term effects are not fully established regarding the durability of the reported responses or patterns of symptom return over extended timeframes.

What Research Shows is Still Uncertain

Key limitations in the research include that comparative evidence is lacking in recent trials for some common indications when measuring the combination against a non-active control. Additionally, data for certain groups remain insufficient, and research is ongoing to assess optimal strategies in populations with complex health profiles.

Key Studies & References

  1. Amoxicillin and Clavulanic Acid: MedlinePlus Drug Information
  2. Clavulanic Acid - StatPearls (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Clamovet (FAQ)


Q: What is the main difference between Clamovet and other medicines used for the same purpose?

The official product information describes Clamovet as a combination drug. It contains the antibiotic amoxicillin and a separate component called clavulanic acid. This acid acts to protect the amoxicillin from degradation by certain bacterial enzymes, which is the key mechanism that distinguishes it from single-ingredient penicillins.

Q: Are there any specific foods I should avoid while using Clamovet?

Official labeling describes taking the medicine at the start of a meal. Taking it at the start of a meal is associated with enhanced absorption and reduced risk of gastrointestinal discomfort. Official drug labeling generally does not list specific foods that must be avoided while using Clamovet.

Q: Can Clamovet cause a skin rash, and what should I look for?

Official labeling states that Clamovet can cause rashes, ranging from mild skin rashes (common) to severe and sometimes fatal skin reactions. Official documents note that discontinuation of the drug is recommended if a rash progresses or if other signs of a severe allergic reaction are observed.

Q: Are there special considerations for older adults using Clamovet?

Official information indicates that caution is advised when treating older adults. This is primarily because this population is more likely to have reduced kidney function. Regulatory guidelines note that dose adjustments may be required in such cases.

Q: What are the long-term safety concerns, if any, with Clamovet?

Nonclinical toxicology studies for long-term use in animals have not been performed to evaluate the potential for cancer-causing effects. Official product information emphasizes that the medicine should only be used for the duration prescribed by a healthcare professional.

Q: Can I take Clamovet if I have a history of liver problems?

Official information states that Clamovet is contraindicated (must not be used) if a patient has a history of liver problems or cholestatic jaundice linked to previous use of the medicine. Caution is also advised for patients with existing liver impairment, and liver function tests may be monitored in such cases.

Q: Why is Clamovet generally recommended for short-term use?

The medicine is approved by regulatory bodies for the treatment of acute bacterial infections. These types of infections typically require short, defined courses of therapy. Official warnings state the drug should only be used to treat bacterial infections, not viral ones.

Q: What are the major contraindications listed for Clamovet?

Regulatory documents list two major groups of contraindications. The first is a history of severe hypersensitivity (allergic) reactions to Clamovet itself, other penicillins, or cephalosporins. The second is a history of cholestatic jaundice or liver dysfunction associated with previous use of this medicine.

Q: Can Clamovet be crushed or chewed, or must it be swallowed whole?

Official labeling states that extended-release tablets are required to be swallowed whole and must not be crushed, broken, or chewed. The handling requirements for other forms, such as immediate-release tablets or oral suspensions, are described separately in the product information.

Q: What does the clinical trial data indicate about Clamovet's efficacy?

Clinical studies detailed in regulatory documents report outcomes for specific bacterial infections. These outcomes, such as those monitored in treating acute otitis media in children and lower respiratory tract infections in adults, are reported in relation to specific susceptible bacteria identified in the trials.

Q: Why is Clamovet prescribed for certain conditions but not others?

Official labeling establishes that the medicine is approved to treat infections caused by specific strains of susceptible bacteria. These include infections in the lower respiratory tract, ear, sinus, skin, and urinary tract. Prescription is guided by these official indications, which are based on data submitted to regulatory authorities.

Q: What happens if I stop taking Clamovet too soon?

Patient counseling information in official documents warns that not completing the full prescribed course may decrease the overall effectiveness of the treatment. Furthermore, it may increase the likelihood that the bacteria causing the infection will develop drug resistance.

Q: Is it common to feel tired while taking Clamovet?

Official adverse reaction reports indicate that fatigue is sometimes reported in post-marketing experience. However, fatigue is not listed as one of the most common side effects, which typically include gastrointestinal issues, headache, and dizziness.

Q: Can Clamovet affect the results of blood tests?

Yes, regulatory information indicates that Amoxicillin and Clavulanate Potassium may affect the results of certain laboratory tests. These include specific types of urine glucose tests and some tests used to measure prothrombin time.

Q: Is it possible to have an allergic reaction to Clamovet if I've never had one before?

Official safety precautions state that serious, and sometimes fatal, hypersensitivity reactions (allergic reactions) can occur in patients. Regulatory documents note that the medicine is recommended to be discontinued immediately if signs of a severe reaction develop, regardless of prior use.

Q: How long does Clamovet typically stay in your system after the last dose?

The pharmacokinetic data provided in regulatory documents gives the elimination half-lives of the active ingredients. The reported half-life is approximately 1.3 hours for amoxicillin and 1.0 hour for clavulanate, meaning the drug is generally eliminated relatively quickly from the body.

Q: Can Clamovet be taken by people who have diabetes?

Patient counseling information includes a caution for individuals with high blood sugar, or diabetes. If such patients test their urine glucose, official guidance notes that this drug may affect the results of certain tests. The choice of appropriate testing methods should be discussed with a healthcare professional.

Q: Does Clamovet interact with birth control pills?

Yes, official drug interaction information states that Clamovet may reduce the effectiveness of oral contraceptives. Regulatory labeling notes that patients should be made aware of this potential risk.

Q: Can people who are lactose intolerant take Clamovet?

The official product description lists lactose as an inactive ingredient contained within the medicine. Individuals with known intolerances can review this component with a healthcare professional.

Q: Does Clamovet have an effect on sleep patterns?

Adverse reaction reports list dizziness and other central nervous system (CNS) effects, such as confusion, as possible side effects. Insomnia or sleep disturbance is not listed as a common side effect in the official documents.

Q: Why might a doctor switch me from a similar drug to Clamovet?

The primary therapeutic purpose of Clamovet is overcoming bacterial resistance. The clavulanic acid component protects the amoxicillin from bacterial enzymes, and a healthcare professional may choose Clamovet when treating an infection caused by a resistant organism.

Q: Does Clamovet affect fertility?

Nonclinical toxicology studies conducted in rats showed no reported effect on fertility or reproductive performance when high doses of the active ingredients were administered. This information is noted in regulatory documents.

Q: Is it necessary to finish the entire course of Clamovet even if I feel better?

Patient counseling information states that the medication is intended to be taken exactly as directed, even if a patient feels better early in the course of therapy. Completing the full course is described in official documents as necessary to manage the infection.

How should Clamovet be stored and disposed of?

The storage and disposal of Clamovet (Amoxicillin/Clavulanic Acid tablets) must strictly adhere to instructions provided in the official regulatory documents.

Storage and Protection

Condition Requirement
Temperature Must not be stored above 25 C.
Environment Protect from light and moisture.
Packaging Store in the original package to maintain protection.
Child Safety Keep out of the sight and reach of children.

The maximum storage temperature is 25 C, and the tablets must remain in the original container to shield the sensitive ingredients from moisture and light. The labeled shelf-life is typically 2 years when stored correctly, with certain packaging requiring use within 30 days of opening.

Disposal Instructions

Any unused medicine or waste material must be disposed of in accordance with local requirements. Patients are instructed to return any leftover antibiotic to a pharmacy for appropriate disposal once the treatment course is finished. This prevents environmental contamination, as medicines should not be discarded via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clamovet found in:

A-Z Index: